ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0003299 | null | Anti-epileptic|antiepileptic|antiepileptics|Antiepileptics|Anti-epileptic Agent [TC]|ANTIEPILEPTICS|antiepileptic drugs|antiepileptic drug|Antiepileptic Agents|Drugs, Antiepileptic|Antiepileptic Drugs|Anti-epileptic Agent|Antiepileptic Agent|antiepileptics drugs|Antiepileptic|Agents, Antiepileptic | Antiepileptic Agents |
C0018120 | An OOCYTE-containing structure in the cortex of the OVARY. The oocyte is enclosed by a layer of GRANULOSA CELLS providing a nourishing microenvironment (FOLLICULAR FLUID). The number and size of follicles vary depending on the age and reproductive state of the female. The growing follicles are divided into five stages: primary, secondary, tertiary, Graafian, and atretic. Follicular growth and steroidogenesis depend on the presence of GONADOTROPINS. | Ovarian Follicle|Follicle of ovary viewed macroscopically|Ovarian follicle, NOS|ovarian follicles|Ovarian Follicles|Follicle|Ovarian follicle|ovarian follicle|Ovarian follicle structure (body structure)|Follicle, Ovarian|Follicle of ovary (viewed macroscopically)|Ovary follicle|Ovarian follicle structure|Follicles, Ovarian|OVARIAN FOLLICLE|Follicle of ovary | Ovarian Follicle |
C0304866 | null | beef insulin|insulin (beef)|Insulin purified beef|Insulin beef|bovine insulin|Beef insulin|Bovine insulin|Beef insulin, NOS|Beef insulin (substance)|Beef insulin-containing product|Insulin (beef)|insulin bovine|Insulin Beef|Product containing beef insulin (product)|INSULIN BEEF|Insulin bovine | Insulin, Beef |
C0074825 | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (Int J Gynaecol Obstet 1992;39(1):3-9) | IGF-Binding Proteins|Somatomedin-Binding Proteins|igf binding protein|Insulin-Like Growth Factor-Binding Protein|IGF-BP - Insulin-like growth factor binding protein|Insulin-Like Growth Factor Binding Proteins|IGF binding protein|IGFBP|igfbp|Somatomedin Binding Proteins|Insulin-like growth factor binding protein (substance)|igf binding proteins|IGF Binding Proteins|Insulin-like growth factor binding protein|insulinlike growth factor binding protein|Insulin-like growth factor-binding proteins | Insulin-Like Growth-Factor-Binding Proteins |
C0077144 | A synthetic derivative of androstane with adrenocortical suppressive properties. Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. (NCI04) | (4Alpha,5alpha,17beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile|4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile|4alpha,5-epoxy-17beta-hydroxy-3-oxoandrostane-2-carbonitrile|Trilostane|Trilostanum|trilostane|Trilostane-containing product|2Alpha-cyano-4alpha,5alpha-epoxyandrostan-17beta-ol-3-one|Trilostane (substance)|Product containing trilostane (medicinal product)|TRILOSTANE|Trilostano | trilostane |
C0077144 | A synthetic derivative of androstane with adrenocortical suppressive properties. Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. (NCI04) | (4Alpha,5alpha,17beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile|4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile|4alpha,5-epoxy-17beta-hydroxy-3-oxoandrostane-2-carbonitrile|Trilostane|Trilostanum|trilostane|Trilostane-containing product|2Alpha-cyano-4alpha,5alpha-epoxyandrostan-17beta-ol-3-one|Trilostane (substance)|Product containing trilostane (medicinal product)|TRILOSTANE|Trilostano | trilostane |
C1193659 | null | Pseudomonas thermotolerans (organism)|Pseudomonas thermotolerans | Pseudomonas thermotolerans |
C1193659 | null | Pseudomonas thermotolerans (organism)|Pseudomonas thermotolerans | Pseudomonas thermotolerans |
C1193659 | null | Pseudomonas thermotolerans (organism)|Pseudomonas thermotolerans | Pseudomonas thermotolerans |
C1193659 | null | Pseudomonas thermotolerans (organism)|Pseudomonas thermotolerans | Pseudomonas thermotolerans |
C0021665 | A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. | Insulin Like Growth Factor I|IGF-1|insulin like growth factor i|Insulin-Like Somatomedin Peptide I|somatomedin c|insulin-like growth factor 1 (IGF-1)|igf i|igf-i|IGF I|Insulin Like Somatomedin Peptide I|SmC - Somatomedin C|Somatomedin C|SM-C|Insulin-like growth factor 1|igf 1|IGF-I|insulin-like growth factor 1|igf-1|Somatomedin C (substance)|IGF-I-SmC|IGF 1 - Insulin like growth factor 1|Insulin-Like Growth Factor I|insulin like growth factor 1|Insulin-like growth factor I|insulin-like growth factor i|Human somatomedin C | Insulin-Like Growth Factor I |
C0010572 | Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. | Cycloheximide|2,6-Piperidinedione, 4-(2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl)-, (1S-(1alpha(S*),3alpha,5beta))-|cycloheximide|cicloheximide|Cycloheximide (substance)|Cicloheximide | Cycloheximide |
C0010934 | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | Actinomycin X 1|Meractinomycin|actinomycin IV|2-bis[cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3|Dactinomycin|Actinomycin-[thr-val-pro-sar-meval]|actinomycin d|Dactinomycine|Dactinomycin-containing product|DACTINOMYCIN|Dactinomycin (substance)|ActD|meractinomycin|Dactinomycinum|ACT-D|actinomycin-[thr-val-pro-sar-meval]|actinomycin-C1|2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide|Actinomycin IV|actinomycin-d|Actinomycin C1|actinomycin X 1|DACTINomycin|Product containing dactinomycin (medicinal product)|ACTINOMYCIN D|DACT|actinomycin C1|Actinomycin D|actinomycin-D|2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3|actinomycin I1|dactinomycine|Actinomycin A IV|AD|Actinomycin I1|Dactinomicina|actinomycin D|dactinomycin | dactinomycin |
C0044551 | A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) | Caprylic alcohol|n-Octyl Alcohol|n Octyl Alcohol|Caprylic Alcohol|Caprylic alcohol (substance)|1 Octanol|Alcohol, n-Octyl|1-octanol|CAPRYLIC ALCOHOL|n Octanol|n-Octanol|1-Octanol | 1-octanol |
C0068004 | A colorless liquid with a fragrant odor. It is used as an intermediate, solvent and in cosmetics. | Alcohol, Heptyl|n Heptanol|Heptanol (substance)|n-Heptanol|1 Heptanol|Heptan-1-ol|1-Heptanol|Heptanol|Heptyl Alcohol|Heptyl alcohol | Heptanol |
C0304866 | null | beef insulin|insulin (beef)|Insulin purified beef|Insulin beef|bovine insulin|Beef insulin|Bovine insulin|Beef insulin, NOS|Beef insulin (substance)|Beef insulin-containing product|Insulin (beef)|insulin bovine|Insulin Beef|Product containing beef insulin (product)|INSULIN BEEF|Insulin bovine | Insulin, Beef |
C0018207 | Supporting cells for the developing female gamete in the OVARY. They are derived from the coelomic epithelial cells of the gonadal ridge. Granulosa cells form a single layer around the OOCYTE in the primordial ovarian follicle and advance to form a multilayered cumulus oophorus surrounding the OVUM in the Graafian follicle. The major functions of granulosa cells include the production of steroids and LH receptors (RECEPTORS, LH). | cells granulosa|Granulosa cell of ovary|Granulosa Cells|Cell, Granulosa|Granulosa cell|granulosa cells|granulosa cell|Ovarian Granulosa Cell|Cells, Granulosa|Granulosa Cell | granulosa cell |
C1522259 | null | Muscle - Striated (Skeletal) (MMHCC)|Mouse Striated Skeletal Muscle | Muscle - Striated (Skeletal) (MMHCC) |
C0018284 | Growth Factors are extracellular signaling molecules (ligands) involved in control of target cell proliferation, cell survival, and cell differentiation. (NCI) | growth factor|growth agent|GROWTH FACTORS|Growth Factors|Growth factors|Growth Factors, Proteins|Growth factor (substance)|Growth Agents|Mitogen|Growth factor, NOS|Growth factor|Growth Factor|growth factors | Growth Factor |
C0242697 | OBSOLETE. The contractile fibers, composed of actin, myosin, and associated proteins, found in cells of smooth or striated muscle. [GOC:mah, ISBN:0815316194] | fiber muscle|Muscle fiber|fibers muscles|myotube|muscle fibre|myotubes|fibers muscle|muscle fibers|muscle fiber | Muscle Fibers |
C0019878 | A thiol-containing amino acid formed by a demethylation of METHIONINE. | Homocysteine, L Isomer|Homocysteine (substance)|2 amino 4 mercaptobutyric acid|homocysteine|Butanoic Acid, 2-Amino-4-Mercapto-|L-homocysteine|Hcy|L-Isomer Homocysteine|Homo-Cys|2-Amino-4-Mercapto-Butyric acid|Homocysteine|Butyric Acid, 2-Amino-4-Mercapto-|l-homocysteine|2-Amino-4-Sulfanylbutanoic Acid|2-amino-4-mercaptobutyric acid|Homocysteine, L-Isomer|2-Amino-4-Mercapto-Butanoic Acid|2-Amino-4-Mercaptobutyric Acid | homocysteine |
C0034917 | null | Glutathione, reduced|reduced glutathione|Reduced Glutathione|Reduced glutathione (substance)|Reduced glutathione|Glutathione, Reduced | Reduced Glutathione |
C0040690 | A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. | Factor, Milk Growth|tgfbeta|Bone-Derived Transforming Growth Factor|Tumor Growth Factor Beta|Transforming growth factors-beta|Bone Derived Transforming Growth Factor|Tumor Growth Factor B|TGF B|Milk Growth Factor|Transforming Growth Factor-Beta|TGF beta|transforming growth factor-beta|tgf b|TGF-Beta|Growth Factor, Milk|transforming growth factor beta|TGF-B|Platelet Transforming Growth Factor|TGF-beta|tgf beta|Transforming Growth Factor-Beta Superfamily|TGFbeta|Transforming Growth Factor beta|tgf-beta|factors growth milk | Transforming Growth Factor beta |
C1511131 | In living cells, chemical reactions that help sustain life and allow cells to grow. | biochemical reactions|Biochemical Reactions|Enzymatic Reaction | Biochemical Reaction |
C0015075 | null | ethylene|Bicarburretted Hydrogen|Ethylene (substance)|ETHYLENE|ethene|Olefiant gas|Elayl|Product containing ethylene (medicinal product)|Ethene|Ethylene-containing product|Ethylene|Acetene | ethylene |
C0018282 | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS). | Inhibitors, Cell Growth|growth inhibitors|growth inhibitor|Cell Growth Inhibitors|inhibitors growth|Inhibitors, Growth|Growth Inhibitors, Cell|cell growth inhibitor | Growth Inhibitors |
C0233794 | Deterioration in memory function. | memory deficits|MEMORY IMPAIRMENT|memory deficit|Memory retention disorder|Deficits, Memory|impairment memory|poor memory|bad memory|Memory impairment|Bad memory|impair memory|Memory problem|Memory Deficits|Deficit, Memory|Poor memory|memory disturbance|MEMORY DISTURBANCE|impairments memory|memory problems|Disturbance of memory|Memory deficit|Impaired memory|memory impairment|MEMORY IMPAIRED|Memory Impairment|memory poor|Memory impairment (finding)|Disturbance of memory, NOS|impaired memory|Memory Deficit|Memory deficits | Memory impairment |
C0025086 | null | Medical Imaging|Imaging, Medical|medical imaging|imaging medical | Medical Imaging |
C0001975 | Alkyl compounds containing a hydroxyl group. They are classified according to relation of the carbon atom: primary alcohols, R-CH2OH; secondary alcohols, R2-CHOH; tertiary alcohols, R3-COH. (From Grant & Hackh's Chemical Dictionary, 5th ed) | ALCOHOLS|class of chemical alcohols|alcohol|alcohol product|Alcohol-containing product|Alcohol, NOS|Alcohols|Alcohol [Chemical Class]|alcohols|alcohol substance|Product containing alcohol (product)|alcohol in any form|alcohols (chemical class)|Alcohol|Alcohol (substance) | Alcohols |
C0014898 | Compounds derived from organic or inorganic acids in which at least one hydroxyl group is replaced by an -O-alkyl or other organic group. They can be represented by the structure formula RCOOR' and are usually formed by the reaction between an acid and an alcohol with elimination of water. | Ester, NOS|Organic Ester|ester|Esters|esters|Ester|Ester (substance) | Esters |
C0001964 | A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate. | Propanol|propyl alcohol|propanol|PROPYL ALCOHOL|1-propanol|1-proponol|Propyl alcohol|n-Propyl alcohol|n-propanol|N-propanol|N-propyl alcohol|Propyl Alcohol|Propan-1-ol (substance)|Alcohol, Propyl|1-Propanol|n-Propanol|Propan-1-ol | 1-propanol |
C0066409 | A methyl ester of methacrylic acid. Methyl methacrylate is a reactive resin, and the polymerized form is used as cement in dentistry, orthopaedic surgery and ophthalmology. The monomer form of this agent has relaxation effect on smooth muscle systemically, which might be a result of nitric oxide-mediated response. | Monomers, Methacrylate Methyl|2-Propenoic acid, 2-methyl- methyl ester|methylmethacrylate|Methyl methacrylate-containing product|Methyl Monomer, Methylmethacrylate|Methacrylate Methyl Monomer|2-Methyl Acrylic Acid Methyl Ester|Diakon|MMA|Methyl Monomer, Methacrylate|Methyl Monomers, Methacrylate|Methyl Methacrylate|Methylmethacrylate Methyl Monomer|2-Methylmethacrylate|methacrylate methyl|Methylmethacrylate Methyl Monomers|Product containing methyl methacrylate (medicinal product)|Monomer, Methylmethacrylate Methyl|2-Propenoic Acid, 2-methyl-, Methyl Ester|Methyl methacrylate (substance)|Monomer, Methacrylate Methyl|Methacrylate Methyl Monomers|Monomers, Methylmethacrylate Methyl|Methyl 2-Methyl-2-propenoate|2-(Methoxycarbonyl)propene|Pegalan|Methylmethacrylate|Methyl Monomers, Methylmethacrylate|METHYL METHACRYLATE|methyl methacrylate|Methyl methacrylate | methylmethacrylate |
C0596066 | any of a series of univalent groups of the general formula CnH2n+1 derived from aliphatic hydrocarbons. | alkyl group | alkyl |
C0001962 | A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. | ethanol|etanol|ETHANOL|ETOH|Methylcarbinol|Drinking alcohol|Alcohol|EtOH|Ethanol-containing product|Ethanol|Alcohol anhydrous|Absolute ethanol|ALCOHOL|methylcarbinol|Alcohol (ethyl)|alcohol ethyl|Hydroxyethane|Äthylalkohol|Absolute Ethanol|Alcohol etílico|éthanol|Spiritus vini|alcohol|Ethyl Alcohol|EtOH - Alcohol|1-Hydroxyethane|Product containing ethanol (medicinal product)|Ethyl alcohol|grain alcohol|Alcohol denatured|ethyl alcohol|Alcohol, denatured|ALCOHOL,ETHYL|Dehydrated ethanol|EtOH - Ethanol|ethanols|Alcool éthylique|Grain alcohol|Grain Alcohol|Alcohol, Grain|absolute ethanol|Äthanol|Alkohol|Alcohol, Ethyl|Ethanol (substance) | ethanol |
C0068008 | null | Hexane|n hexane|Hexane (substance)|n-Hexane|hexane|n-hexane|HEXANE | hexane |
C1260969 | Any doughnut-shaped device. | Ring|Ring, device|rings|Ring, device (physical object)|ring [physical object]|RING|ring|Ring Device | Ring device |
C0022023 | An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as CATIONS; those with a negative charge are ANIONS. | ion|charged particles|ions|Ion, NOS|Ion|Ions | Ions |
C0086983 | The generic term for salts derived from silica or the silicic acids. They contain silicon, oxygen, and one or more metals, and may contain hydrogen. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th Ed) | silicate|silicates|SILICATE|Silicate salt|Silicate salt, NOS|Silicates|Silicate|Silicate salt (substance) | Silicates |
C0009429 | The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. | Multimodal Treatment|combination therapies|Therapies, Combined Modality|multimodality treatment|Treatment, Multimodal|Multimodal Treatments|Combination therapy|Multimodal Therapy|Combination therapy (regime/therapy)|Combined Treatment Modalities|combination therapy|Modality Therapy, Combined|cotreatment|combined modality therapy|concurrent therapy|Multimodality Therapy|Combined Modality Therapies|Combination Therapy|Therapy, Combined Modality|Combined Modality Therapy|Treatments, Multimodal|multimodal treatment|Combined modality therapy|Combined Modality Treatment|Combined Treatment|multimodal treatments|multimodality therapy|combined treatment|Modality Therapies, Combined|Multimodality Treatment | Combined Modality Therapy |
C0524910 | INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS. | c chronic hepatitis|hepatitis c chronic|Chronic hepatitis C (disorder)|chronic hepatitis c|Chronic hepatitis C|Chronic Hepatitis C|Chronic type C viral hepatitis | Hepatitis C, Chronic |
C0015695 | Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. | LIVER FATTY|hepatic lipidosis|Fatty liver|fatty change liver|LIVER FATTY INFILTRATION|LIVER FATTY METAMORPHOSIS|Hepatic lipidosis|Fatty changes in liver|fatty liver infiltration|Liver, Fatty|change fatty liver|liver fatty infiltration|liver steatosis|LIVER FATTY DEGENERATION|fatty livers|INFILTRATION FATTY LIVER|fatty infiltration liver|changes fatty liver|hepatitic steatosis|DEGENERATION FATTY LIVER|hepatic steatosis|Fatty metamorphosis, liver|fatty liver metamorphosis|liver fatty change|Fatty infiltration of liver|LIVER FATTY CHANGE|steatosis of liver|METAMORPHOSIS FATTY LIVER|Fatty Liver|fatty liver|FATTY LIVER | Fatty Liver |
C0023439 | A rare acute myeloid leukemia characterized by abnormal EOSINOPHILS in the bone marrow. | Leukemia, Acute Eosinophilic|Acute eosinophilic leukemia|Acute eosinophilic leukaemia|Acute Eosinophilic Leukemia|Acute eosinophilic leukemia (disorder)|Eosinophilic Leukemias, Acute|Eosinophilic Leukemia, Acute|Leukemia, Eosinophilic, Acute|Acute Eosinophilic Leukemias|Leukemias, Acute Eosinophilic | Leukemia, Eosinophilic, Acute |
C0023439 | A rare acute myeloid leukemia characterized by abnormal EOSINOPHILS in the bone marrow. | Leukemia, Acute Eosinophilic|Acute eosinophilic leukemia|Acute eosinophilic leukaemia|Acute Eosinophilic Leukemia|Acute eosinophilic leukemia (disorder)|Eosinophilic Leukemias, Acute|Eosinophilic Leukemia, Acute|Leukemia, Eosinophilic, Acute|Acute Eosinophilic Leukemias|Leukemias, Acute Eosinophilic | Leukemia, Eosinophilic, Acute |
C0035525 | A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. | RTCA|1-.beta.-D-Ribofuranosyl-1H-1,2, 4-triazole-3-carboxamide|Ribavirin (substance)|RIBA|1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl-|1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide|Ribavirina|1-Beta-D-ribofuranosyl-1,2,4-triazolo-3-carboxamide|1-beta-D-ribofuranosyl-1,2,4-triazolo-3-carboxamide|Ribavirin|1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide|ribovirin|Ribavirin-containing product|Product containing ribavirin (medicinal product)|RBV|Ribavirine|1-Beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide|1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide|Ribavrin|Tribavirin|RIBAVIRIN|Ribovirin|ribavirin|Ribavirinum | ribavirin |
C0677862 | A specimen obtained by biopsy, which is a process of removing tissue from living patients for diagnostic examination. | Biopsy Sample|Biopsy Specimen|biopsy specimen|Biopsy sample (specimen) | Biopsy sample |
C0152254 | Acumulation of adipose tissue in intracytoplasmic or extracellular spaces. | Degeneration, fatty|Fatty Change|steatosis|changes fatty|Fatty degeneration (morphologic abnormality)|Fatty change|fatty change|fatty degeneration|fatty metamorphosis|FATTY CHANGE|Fatty degeneration|Fatty metamorphosis|Steatosis|Lipoid degeneration | Fatty degeneration |
C0006521 | Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. | butyrate|Butyrates | Butyrates |
C0006521 | Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. | butyrate|Butyrates | Butyrates |
C0449575 | null | Histological finding (attribute) | Histological finding |
C0016059 | Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. | Fibrous repair|Fibroplasia|desmoplasia|fibrosis|fibroses|FIBROSIS|Fibrosis (qualifier value)|fibroplasia|Desmoplasia|Fibrosis|Fibroses|Fibrosis (morphologic abnormality)|Fibrous thickening|Fibrosis, NOS|fibrosis (formation of excess fibrous connective tissue)|Fibroplasia, NOS|fibrose|Fibrous tissue formation|Fibrous replacement | Fibrosis |
C0227515 | Small channels in the liver situated between the interlobar ducts and the lobules, which carry bile from the canaliculi and Canals of Hering to the intrahepatic bile ducts. | Ductus biliferi interlobulares|Interlobular bile ducts|Set of interlobular bile ducts|Interlobular bile duct|Structure of interlobular bile duct|Portal bile ductule|Interlobular Bile Duct|Structure of interlobular bile duct (body structure)|Interlobular bile ducts set | Interlobular bile duct |
C0009714 | A congenital disorder usually inherited in an autosomal recessive pattern. It affects the hepatobiliary system and the kidneys. It is characterized by liver fibrosis, portal hypertension, and renal cysts. | congenital liver fibrosis|Congenital Fibrose Liver|congenital fibrosis liver|HEPATIC FIBROSIS, CONGENITAL|congenital hepatic fibrosis|Congenital Hepatic Fibrosis|Excessive buildup of connective tissue and scarring of liver at birth|Congenital hepatic fibrosis|CONGENITAL HEPATIC FIBROSIS|Hepatic fibrosis, congenital|Congenital hepatic fibrosis (disorder) | Hepatic Fibrosis, Congenital |
C0030312 | Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets. | Pancytopenia (disorder)|pancytopenia|pancytopenias|bone marrow failure|Pancytopenia|Pancytopenia (finding)|Low blood cell count|Pancytopenias|PANCYTOPENIA|Bone Marrow Failure | Pancytopenia |
C0022680 | A usually autosomal dominant and less frequently autosomal recessive genetic disorder characterized by the presence of numerous cysts in the kidneys leading to end-stage renal failure. The autosomal dominant trait is associated with abnormalities on the short arm of chromosome 16. Symptoms in patients with the autosomal dominant trait usually appear at middle age and include abdominal pain, hematuria, and high blood pressure. Patients may develop brain aneurysms and liver cysts. Patients with the autosomal recessive trait present with progressive renal failure early in life and symptoms resulting from hepatic fibrosis. The autosomal recessive trait is associated with abnormalities of chromosome 6. Polycystic kidney disease may also result as a side effect in patients on renal dialysis. | Diseases, Polycystic Renal|Fibrocystic Renal Disease|congenital polycystic kidney|Polycystic kidney disease (disorder)|Polycystic kidney|Polycystic kidney, unspecified type|KIDNEY POLYCYSTIC|PCK - Polycystic kidney disease|polycystic kidneys|Disease, Polycystic Renal|polycystic kidney diseases|Kidney Disease, Polycystic|PKD - Polycystic Kidney Disease|KIDNEY, POLYCYSTIC DISEASE|Diseases, Polycystic Kidney|PKD - Polycystic kidney disease|Polycystic Kidney Diseases|Disease, Polycystic Kidney|Polycystic Renal Disease|Polycystic Kidney|polycystic kidney|POLYCYSTIC RENAL DISEASE|POLYCYSTIC KIDNEY|Polycystic kidney disease|Polycystic kidney dysplasia|polycystic kidney disease|Renal Disease, Polycystic|KIDNEY, POLYCYSTIC|Polycystic Kidney Disease|Renal Diseases, Polycystic|Kidney Diseases, Polycystic|polycystic renal disease|Polycystic Renal Diseases | Polycystic Kidney Diseases |
C0024894 | INFLAMMATION of the BREAST, or MAMMARY GLAND. | BREAST INFLAMMATION|MASTITIS|Breast infection|Mastitis NOS|Mastitis, NOS|Mastitis|mastitis | Mastitis |
C0030637 | A species of gram-negative, facultatively anaerobic, rod-shaped bacteria normally found in the flora of the mouth and respiratory tract of animals and birds. It causes shipping fever (see PASTEURELLOSIS, PNEUMONIC); HEMORRHAGIC BACTEREMIA; and intestinal disease in animals. In humans, disease usually arises from a wound infection following a bite or scratch from domesticated animals. | Pasteurella multocida|P. multocida|Bacterium multocidum|pasteurella multocida|Pasteurella gallicida|Pasteurella multocida (organism)|Pasteurella cholerae-gallinarum|PASTEURELLA MULTOCIDA|Pasteurella septica|Micrococcus gallicidus | Pasteurella multocida |
C0085490 | A species of facultatively anaerobic, Gram negative, rod shaped bacteria in the phylum Fusobacteria. This species is nonmotile, beta hemolytic, and ferments D sorbitol, D xylose and maltose, but not trehalose. M. haemolytica is a commensal organism of the upper respiratory tract of ruminants but may become pathogenic, causing pneumonia. | MANNHEIMIA HAEMOLYTICA|Pasteurella haemolytica|Mannheimia hemolytica|Mannheimia haemolytica (organism)|Mannheimia haemolytica|Pasteurella hemolytica | Mannheimia haemolytica |
C0035204 | Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available. | Disorder, Respiration|Respiratory disease|Respiration Disorders|disorder respiratory|Disease of respiratory system, NOS|Respiratory disorder|respiratory disorder|Respiratory system disease|Personal history of unspecified disease of respiratory system|Diseases of the respiratory system|Unspecified disease of respiratory system|RESPIRATORY DISORDER (NOS)|Respiratory Disorder|DISORDER RESPIRATORY SYSTEM|Disorder of respiratory system|Disorders, Respiration|Disorder of respiratory system (disorder)|Respiratory Diseases|Respiratory disease NOS|Respiratory disorder, NOS|RESPIRATORY DISORDER|Diseases and Syndromes of Respiratory System|Disorder of Respiratory System|DISEASES OF THE RESPIRATORY SYSTEM|RESPIRATORY SYSTEM DISORDER OF|disorders respiratory|Respiration Disorder|RESPIRATORY DISEASES: GENERAL TERMS|Disease or syndrome of respiratory system|Respiratory System Disorder | Respiration Disorders |
C0275799 | null | Staphylococcal mastitis (disorder)|Staphylococcal mastitis | Staphylococcal mastitis |
C0026251 | Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase. | MGBG|pyruvaldehyde bis(amidinohydrazone)|MGGH|Methylglyoxal Bisguanylhydrazone|MITOGUAZONE|Methylglyoxal bis(amidinohydrazone)|Mitoguazona|Mitoguazone|mitoguazone|methylglyoxal bis(guanylhydrazone)|methylglyoxal bis guanylhydrazone|guanylhydrazone|Mitoguazonum|Methylglyoxal Bis(guanylhydrazone)|methylglyoxal bisguanylhydrazone|1,1'-[(methylethanediylidene)dinitrilo)diguanidine|1,1'-((methylethanediylidene)dinitrilo)diguanidine|methylglyoxal bis(amidinohydrazone)|2,2"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]|mga|Hydrazinecarboximidamide, 2,2'-(1-methyl-1,2-ethanediylidene)bis- | Mitoguazone |
C1335804 | One of two transcriptional adaptor/HAT (histone acetyltransferase) complexes, SAGA includes SPT8, ADA2, NGG1, SPT20 (or SPT3 or SPT7), SGF29 [29 kD subunit], SGF73 [73 kD subunit]. (from SGD and NCI) | SPT/ADA/Gcn5 Acetyltransferase|SAGA | SPT/ADA/Gcn5 Acetyltransferase |
C0029921 | Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided. | out-patient|Out-patient|Outpatient|Out patients|out-patients|Outpatients|outpatient|Outpatient (person)|Out-patients|outpatients | Outpatients |
C0019993 | The confinement of a patient in a hospital. | hospitalisations|Hospitalizations|hospitalization|hospitalizations|hospitalisation|Inpatient care|Hospitalization|HOSPITALIZATION|inpatient treatment|inpatient care|Inpatient care (regime/therapy) | Hospitalization |
C0039651 | Closely congeneric derivatives of the polycyclic naphthacenecarboxamide. (Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1117) | Tetracyclines | Tetracyclines |
C0205991 | Deliberate stimulation of a host's immune response via administration of antigens or immunologic adjuvants. | active immunization|Immunization, active|Administration of vaccine to produce active immunity|Active Immunization|Immunization, Active|Administration of vaccine to produce active immunity (procedure)|Active immunization|Active Immunizations|Active immunisation|Immunizations, Active | Administration of vaccine to produce active immunity |
C0011306 | Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). | dendritic cells|Dendritic Cell|Cells, Dendritic|cell dendritics|Dendritic cell|cell dendritic|cells dendritic|Dendritic cells|Dendritic Cells|dendritic cell|Cell, Dendritic | Dendritic Cells |
C0019169 | The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. | hepatitis B virus HBV|Hepatitis Virus, Homologous Serum|B virus, Hepatitis|human hepatitis B virus|Hepatitis B virus|hbv hepatitis b virus|human hepatitis B virus HBV|MS-2 virus|Hepatitis B virus (organism)|hepatitis B virus, HBV|hepatitis B virus|Hepatitis B Virus|Serum hepatitis virus|HEPATITIS B VIRUS|Hepatitis associated virus|hepatitis B virus (HBV)|HBV|Virus-Hepatitis B|HBV - Hepatitis B virus|Human hepatitis B virus|Hepatitis B viruses|viruses, Hepatitis B | hepatitis B virus |
C0439640 | null | dendritic|Dendritic|Dendritic (qualifier value) | Dendritic |
C0039195 | Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. | CTL|Killer T lymphocyte|Cytotoxic T-lymphocyte|Cytotoxic T Cell|cytotoxic T cell|Lympholytic Cells, Cell-Mediated|cytotoxic T lymphocyte|Cell Mediated Lympholytic Cells|Cell-Mediated Lympholytic Cell|Killer T cell|Cytotoxic T Lymphocytes|Tc cell|T-Lymphocyte, Cytotoxic|cytotoxic t cell|CTL cell|Cytolytic T-Cell|Cells, Cell-Mediated Lympholytic|Cytotoxic T Cells|T Lymphocytes, Cytotoxic|T-cytotoxic cell|Lympholytic Cell, Cell-Mediated|cytotoxic t lymphocyte|killer t cell|Cytotoxic T lymphocyte (cell)|CD3+CD8+ Lymphocyte|Cytotoxic T cell|Cytotoxic T-Lymphocytes|Cell, Cell-Mediated Lympholytic|T-Lymphocytes, Cytotoxic|Cytotoxic T-Lymphocyte|Cytotoxic T lymphocyte|cytotoxic t cells|cells killer t|killer T cell|Cell-Mediated Lympholytic Cells|killer t cells | Cytotoxic T-Lymphocytes |
C0032174 | null | Platelet adhesion, function|platelet adhesion|Platelet adhesion, function (observable entity)|Platelet adhesion | Platelet adhesion, function |
C1171312 | The process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and/or excretes the end products of body metabolism in the form of urine. [GOC:dph, GOC:mtg_kidney_jan10, ISBN:0124020607, ISBN:0721662544] | nephrogenesis|development kidney|kidney development | kidney development |
C0231048 | The primordial kidney that develops from the INTERMEDIATE MESODERM in the embryos of vertebrates, and is succeeded by the MESONEPHROS. In higher vertebrates and humans, the pronephros is a vestigial and transient structure. | Pronephric structure|Pronephroi|Pronephros|Pronephric structure (body structure) | Pronephric structure |
C1185625 | <p>A named tag set for metadata used to populate a security category label field that "segments" an IT resource per policy by indicating that access and use is restricted to members of a defined community or project. (HL7 Healthcare Privacy and Security Classification System)</p><p><i>Usage Note:</i>This is the healthcare analog to the US Intelligence Community's concept of a Special Access Program. Compartment codes may be used in as a field value in an initiator's clearance to indicate permission to access and use an IT Resource with a security label having the same compartment value in security category label field.</p><p>Map: Aligns with ISO 2382-8 definition of Compartment - "A division of data into isolated blocks with separate security controls for the purpose of reducing risk."</p> | compartment|Compartments|Set of compartments|Compartments set|Compartment|compartments | Anatomical compartments |
C1283945 | An epithelial streak that arises in the cervical region of the developing embryo; is a precursor to the Wolffian duct, which connects the pronephric kidney to the urogenital sinus. | Pronephric Duct|Pronephric duct (body structure)|Pronephric duct | Pronephric duct |
C0025485 | The middle germ layer of an embryo derived from three paired mesenchymal aggregates along the neural tube. | Mesoderm structure (body structure)|Mesoderm, NOS|Mesoderm structure|Mesoderm|mesoderm | Mesoderm |
C0205097 | Backwards; in a direction toward the tail or posterior extremity of the body. | Caudal|caudal|Caudad|Caudal (qualifier value)|CAUDAL|caudad | Caudal |
C0033362 | A pancreatic polypeptide of about 110 amino acids, depending on the species, that is the precursor of insulin. Proinsulin, produced by the PANCREATIC BETA CELLS, is comprised sequentially of the N-terminal B-chain, the proteolytically removable connecting C-peptide, and the C-terminal A-chain. It also contains three disulfide bonds, two between A-chain and B-chain. After cleavage at two locations, insulin and C-peptide are the secreted products. Intact proinsulin with low bioactivity also is secreted in small amounts. | Proinsulin|proinsulin|Proinsulin (substance) | Proinsulin |
C0060405 | A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin. | 7-(2 (2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid|cefdinir|(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid|Cefdinir-containing product|Product containing cefdinir (medicinal product)|5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)-1-oxoethyl)amino)-3-ethenyl-8-oxo-, (6R,7R)-|(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid|CFDN|Cefdinir|Cefdinir (substance)|CEFDINIR|Cefdinirum | cefdinir |
C0317603 | A species of facultatively anaerobic, Gram positive, rod shaped bacteria in the phylum Firmicutes. This species is nonmotile, ferments L arabinose, esculin and sucrose, catalase negative and alpha galactosidase positive. L. fermentum is a commensal organism of the urogenital tract with probiotic activity. | Bacillus d|Lactobacterium fermentum|Lactobacillus fermentum (organism)|Lactobacillus fermentum|LACTOBACILLUS FERMENTUM|Bacillus casei d|Lactobacillus cellobiosus | Lactobacillus fermentum |
C0002245 | Enzymes that catalyze the endohydrolysis of 1,4-alpha-glycosidic linkages in STARCH; GLYCOGEN; and related POLYSACCHARIDES and OLIGOSACCHARIDES containing 3 or more 1,4-alpha-linked D-glucose units. | 1,4-alpha-D-Glucan glucanohydrolase|4-Alpha-D-Glucan Glucanohydrolase|Alpha Amylase|alpha 1,4 D Glucanglucanohydrolase|alpha Amylase|Alpha-Amylase|Amylase A|alpha-Amylases|Amylase AD|Amylase, pancreatic|Endoamylase|alpha-1,4-D-Glucanglucanohydrolase|1,4-Alpha-D-Glucan Glucanohydrolase|EC 3.2.1.1|alpha-Amylase|Glycogenase|alpha Amylases | alpha-Amylases |
C0021186 | A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. | Indapamidum|Product containing indapamide (medicinal product)|Indapamide (substance)|Indapamid|Indapamida|INDAPAMIDE|indapamide|Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-|Indapamide|Indapamide-containing product|Metindamide | indapamide |
C0061323 | A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer duration of action. This agent is metabolized by CYP2C9 and shows peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity. | Glimepiride (substance)|1-(4-(2-(3-ethyl-4-methyl-2-oxo-3-pyrrolinecarboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea|Glimépiride|Glimepirida|glymepiride|Product containing glimepiride (medicinal product)|glimepiride|Glimepiride-containing product|Glimepiride|GLIMEPIRIDE|Glimepiridum | glimepiride |
C0185115 | The act of pulling out, including the process of obtaining something from a mixture or compound by chemical or physical or mechanical means. | extraction|Extraction, NOS (for tooth extraction see Section 60)|extraction procedures|extractions|Extraction, NOS|REMOVAL|Extraction - action|Extraction (procedure)|Extraction|Extracted|Extraction - action (qualifier value)|extraction procedure | Extraction |
C0444584 | null | Body as a Whole|Whole Body|Body, Whole|Whole body (qualifier value)|Whole body|body whole|whole body|Body|BODY | Whole body |
C0030520 | A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. | PTH - Parathyroid hormone|Product containing parathyroid hormone agent (product)|Parathyroid hormone (rDNA)|Parathyroid hormone|PTH (1-84)|Parathormone preparation, NOS|Intact parathyroid hormone (substance)|Parathyroid hormone agent|parathyroid hormone|Hormone, Parathyroid|Parathormone, NOS|Parathormone|PARATHYROID HORMONES|Parathyroid extract, NOS|Parathyroid hormone (1-84) human recombinant|Parathyroid Hormone|parathormone|Parathyroid hormone agent (substance)|PARATHYROID HORMONE|Parathyroid hormone, NOS|PTH(1-84)|Parathyrin|Parathyroid hormone preparation, NOS|Parathyroid Hormones|parathyroid hormones|Parathyroid Hormone (1-84)|Parathyroid hormone agent-containing product|PTH|parathyrin|PARATHYROID HORMONE PREPARATIONS | parathyroid hormone |
C0033497 | A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. | PROPRANOLOL|Propranolol-containing product|β-Propranolol|1-[(1-Methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol|propranolol|Propranololum|1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol|Propranolol (substance)|Product containing propranolol (medicinal product)|Propranolol|beta-Propranolol|Propanolol|Propanalol|Propranololo|2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-|1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol|propanolol | propranolol |
C0853662 | null | oestrogen deficiency|deficiencies estrogen|deficiency estrogen | estrogen deficiency |
C0379199 | null | (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate|1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate|Ibandronate (substance)|Ibandronate|ibandronate|IBANDRONATE | ibandronate |
C0379199 | null | (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate|1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate|Ibandronate (substance)|Ibandronate|ibandronate|IBANDRONATE | ibandronate |
C0149741 | Fluid that seeps out of one or both nipples of the breast. | Discharge, Nipple|Nipple discharge|breast discharges|breast discharge|Discharges, Nipple|BREAST DISCHARGE|Discharge from nipple|Nipple discharge symptom|Observation of nipple discharge|nipple discharge|Nipple Discharges|Nipple Discharge|Breast discharge|Nipple discharge symptom (finding)|Discharge from nipple (disorder)|discharge from nipple|NIPPLE DISCHARGE | nipple discharge |
C0085105 | The inspection of one's breasts, usually for signs of disease, especially neoplastic disease. | breast self examination|breast examinations self|self breast examination|breast self-examination|Self-Examination, Breast|BSE|Self Examination, Breast|Breast Self-Examinations|breast self-exam|Breast Self Examination|Self-Examinations, Breast|Breast Self-Surveillance|Breast self-examination|breast self-examinations|Breast self-examination (procedure)|Breast Self-Examination|breast examination self | Breast Self-Examination |
C0006147 | The nursing of an infant at the breast. | breast fed infant|BF - Breastfed|Breast fed|breastfeedings|breastfeeding|Infant breastfed|breastfeed|breast fed|Breast fed (finding)|breast fed infants|breast feed|Feeding, Breast|Breast Feeding|BREASTFEEDING|BREAST FEEDING|Breast feeding|Breast feeding, NOS|breasting feeding|breast feeding|breast feedings|Lactation|BF - Breastfeeding|Nursing|Breastfeeding | Breast Feeding |
C0022925 | The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. | LACTATION|Milk Secretion|Lactation, function (observable entity)|Lactation|milk secretion|Lactation, NOS|Milk Secretions|lactation|Lactation, function | Lactation |
C0673606 | null | implanon|Implanon | Implanon |
C0021900 | Contraceptive devices placed high in the uterine fundus. | INTRAUTERINE DEVICE|Contraceptive IUD|Intra-uterine device-IUD|devices intrauterine|Intrauterine device|devices intra uterine|IUD, Contraceptive|intrauterine device|Intrauterine Contraceptive Device|intrauterine devices (IUD)|Device, Intrauterine Contraceptive|Devices, Intrauterine Contraceptive|IUD|IUD - intrauterine contraceptive device|Contraceptive IUDs|Intrauterine Device|IUCD|iuds|intra uterine device|Intrauterine contraceptive device|Device, Intrauterine|Intra-uterine device|intrauterine devices|Intrauterine Contraceptive Devices|intra-uterine device|device intrauterine|Devices, Intrauterine|Contraceptive Devices, Intrauterine|IUDs, Contraceptive|Contraceptive Device, Intrauterine|iucd|IUCD - intrauterine contraceptive device|Intrauterine contraceptive device (physical object)|Intrauterine Devices | Intrauterine Devices |
C0243320 | null | null | Reoplex 346 |
C0243320 | null | null | Reoplex 346 |
C1174739 | null | velcade|Velcade | Velcade |
C1176309 | A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. | BORTEZOMIB|[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid|Bortezomib (substance)|[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid|N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide|Bortezomib|bortezomib|Product containing bortezomib (medicinal product)|Bortezomib-containing product | bortezomib |
C1443643 | Compounds that inhibit the function or proteolytic action of the PROTEASOME. | Inhibitors, Proteasome|Proteasome inhibitor|proteasome inhibitor|Product containing proteasome inhibitor (product)|Inhibitor, Proteasome|Proteasome Inhibitors|Proteasome Inhibitor|Proteasome inhibitor-containing product|Substance with proteasome inhibitor mechanism of action (substance)|Proteasome Endopeptidase Complex Inhibitors|Substance with proteasome inhibitor mechanism of action | Proteasome inhibitor |